Uncertainty, due to the lack of drugs, vaccines and treatments for diabetes, cancer, post-transplant and high blood pressure, marks the beginning of 2023 and the same path is envisioned in 2024, the Cerodesabasto collective cautioned.
Promoted by the Nosotrxs organization, which brings together patients, family members, doctors, organizations, and academics to gain effective access to drugs and medical supplies, it indicated that the main reason for the shortage is that “by doing so they are raising high Direct allotment buys at prices, buys less than the same investment”.
It explains that, although distribution has improved, there are still complaints due to shortages and shortages of drugs for cancer treatment in different regions of the country, such as fluorouracil, acyclovir (antiviral), trimethotropin (antibiotic), heparin (anticoagulants), catheter caps, vincristine, filgrastim, trastuzumab, chloropyramine, others.
For diabetes: metformin, dapagliflozin, insulin isophane, insulin glargine, Insulex, and diatagnectin, among others. For high blood pressure: Telmisartan, Olmesartan, Losartan, others. and in vaccines against influenza and COVID.
He explained that, according to a review by the Mexican Pharmaceutical Institute (INFAM), “more than 50% of direct awards have significant participation.”
They argued that “consolidated purchases continue to show only a partial presence in procurement, with serious implications for the general behavior of the sector, increasing acquisitions through direct rewards.”
“Logistics and distribution which has not been resolved is worrisome and it generates disparate supply levels between units and institutions. Consolidated procurement for 2023-2024 shows delay in their processes for drugs and medical supplies, which is will prompt them to resolve it hastily and at high cost,” he asserted.
For this reason, he indicated, “7 out of 10 Mexicans with diabetes are unable to control their disease. Between 2020 and 2021, the largest reductions were for the treatment of cancer, diabetes, post-transplant and high blood pressure. We are worried that by 2023 and 2024 the situation will be similar to the last four years,” he explained.
And he stressed that “according to information from the Ministry of Finance, there is an under-exercise in health spending of more than 20 billion pesos in 2022.”
missing
For the treatment of cancer:
florrosillo
acyclovir
trimetropina
heparin
catheter plug
vincristina
filgrastim
trastuzumab
chloropyramine
For Diabetes:
metformin
dapagliflozin
isophane insulin
insulin glargine
insulex
Ditagnictine
For high blood pressure:
telmisartan
olmesartan
losartan
Vaccines:
influenza
covid
Source: Financial
